Register to get unlimited access to Citywire’s fund manager database. Registration is free and only takes a minute.

All Stories

Chris Rice: the cycle is ‘flashing alarm bells’

Sanditon's European equity manager has significantly increased his cash weighting as he becomes increasingly worried over the economic climate.

Royal London AM's Hussain: the last Trump trade

Although the Trump trade is rapidly unwinding Azhar Hussain sees at least one area where the president could still have an impact.

Who exactly is behind the £47 million bid for Thesis?

There are some familiar figures behind the acquisition, with several LGT Capital private equity vehicles and property investors, the Slowe family, providing part of the funding.

FCA funds study: six things Hargreaves Lansdown wants to see

Hargreaves has identified six things it would like to see into tomorrow's crucial FCA Asset Management study.

Hedge manager takes stake in UK family office firm

Hedge fund house P Schoenfeld Asset Management has taken a minority stake in private office investment advice firm CdR Capital

Why this ex-UBS private banker blew the whistle

Bradley Birkenfeld discusses the importance of whistle blowers to society and shares his past experiences with UBS.

Europe's 10 most 'dynamic' cities

Savills Investment Management has released its index highlighting Europe's 10 most dynamic cities.

Old Mutual GI appoints two fund veterans as non-execs

Asset management veterans Jon Little and Richard Wohanka have joined the Old Mutual Global Investors board of directors.

The time has come for innovative fund fees

With the FCA study around the corner, Orbis director Dan Brocklebank takes a look at how firms could alter their fee structures to improve the industry's reputation.

Cornelian Asset Managers: the Scottish boutique proving its worth across the UK

Investment Trust video
Play IBT's Craig on the Trump impact for biotech

IBT's Craig on the Trump impact for biotech

Ailsa Craig of the International Biotechnology trust highlights the M&A activity seen in the biotechnology sector this year.

Comment